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Background: This phase II study aims to evaluate the efficacy and safety of biweekly cetuximab in combination
with oxaliplatin, leucovorin, and fluorouracil (FOLFOX-4) as first-line treatment of metastatic wild-type KRAS colorectal
cancer.
Methods: Previously untreated patients with wild-type KRAS tumours received biweekly cetuximab (500 mg/m2 on day
1) plus FOLFOX-4 (oxaliplatin 85 mg/m2 on day 1, leucovorin 200 mg/m2 on days 1 and 2, and fluorouracil as a 400 mg/
m2 bolus followed by a 22-hour 600 mg/m2 infusion on day 1 and 2). Treatment was continued until disease progression,
onset of unacceptable toxicities, metastases surgery, or discontinuation request. The primary endpoint was ORR.
Results: The intention-to-treat population included 99 patients with a median age of 64.1 years (range, 34-82). The ORR
was 60.6% (95% CI, 50.3% to 70.3%). The median follow-up was 17.8 months; the median OS and PFS were 20.8 and
10.1 months, respectively. Metastases from colorectal cancer were surgically resected in 26 (26.3%) patients, with complete
resection achieved in 18 (69.2%) patients. Median PFS and OS in patients undergoing metastatic resection were 12.6 and
29.5 months, respectively. The most common grade 3-4 toxicities were neutropenia (32.3%), acne-like rash (15.2%) and
diarrhoea (11.1%).
Conclusions: The efficacy of the biweekly combination of cetuximab with FOLFOX-4 in patients with wild-type KRAS
tumours supports the administration of cetuximab in a dosing regimen more convenient for patients and healthcare
providers. The activity of the biweekly administration is similar to what has been reported for the weekly regimen.
Reported toxicity was also consistent with the known toxicity profile of weekly cetuximab.
Trial registration: EudraCT Number 200800690916
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Colorectal cancer (CRC) is the second most common
cancer and the second leading cause of cancer mortality
in Europe [1]. The major cause of death in CRC are dis-
tant metastases [2]. It is expected that approximately
25% of patients diagnosed with CRC present with metas-
tasis at initial diagnosis, whereas approximately 50% of* Correspondence: lcirera@mutuaterrassa.es
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article, unless otherwise stated.patients will develop metastatic CRC (mCRC) during the
follow-up [3].
Significant advances in the treatment of mCRC have
been made within the last years after decades of only mod-
est progress with 5-fluorouracil (5-FU) monotherapy.
Consequently, the combination of oxaliplatin or irinotecan
with 5-FU have markedly improved treatment outcomes
[4-6]. Furthermore, the addition of targeted therapies to
conventional mCRC chemotherapy regimens has resulted
in further improvement of efficacy results [7].d Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Fernandez-Plana et al. BMC Cancer 2014, 14:865 Page 2 of 8
http://www.biomedcentral.com/1471-2407/14/865Cetuximab, a chimeric monoclonal antibody that targets
the epidermal growth factor receptor (EGFR), is currently
a component of the standard of care for mCRC [8]. Two
randomised clinical trials demonstrated the clinical ef-
ficacy of adding weekly cetuximab to irinotecan- or
oxaliplatin-based chemotherapy regimens in the first-line
treatment of patients with wild-type KRAS mCRC [9-12].
The standard cetuximab dosing regimen, both as a
monotherapy and in combination with chemotherapy,
involves an initial intravenous infusion of 400 mg/m2
with subsequent weekly doses of 250 mg/m2. In contrast,
a biweekly dosing schedule -every 14 days- would offer
several advantages in terms of convenience and a more
economical use of healthcare resources [13]. Moreover,
these benefits would be enhanced in mCRC treatment
regimens as standard first-line chemotherapy regimens
approved for use in combination with cetuximab in
wild-type KRAS mCRC, such as oxaliplatin, 5-FU infu-
sion and leucovorin (FOLFOX) or irinotecan plus 5-FU
infusion and leucovorin (FOLFIRI), are already adminis-
tered in a biweekly basis.
The feasibility of a biweekly cetuximab administration
schedule was demonstrated in a two-part phase I dose-
escalation study [14]. This study demonstrated that
cetuximab can be safely administered as single agent or
in combination with FOLFIRI at doses between 400 and
700 mg/m2 in a biweekly schedule, and 500 mg/m2 was
established as the recommended dose on the basis of
pharmacokinetic exposure data [14]. Furthermore, data
provided by several studies involving a combined regi-
men of cetuximab and irinotecan support the hypothesis
that safety and efficacy of a biweekly schedule are similar
to a weekly schedule [15-17].
Seeking to increase convenience for patients and
healthcare providers, this phase II study was designed
with the aim to evaluate the efficacy and safety of bi-
weekly cetuximab in combination with FOLFOX-4 in
the first-line treatment of wild-type KRAS mCRC.
Methods
Study design
This multicentre, single-arm, open-label, phase II clinical
trial was carried out in 15 Spanish centres (EudraCT
Number: 2008-006909-16). The local authorities and
ethic committees or institutional review boards at each
participating centre approved the study protocol and its
amendments. The study was conducted in accordance
with the ethical principles of the Declaration of Helsinki.
All patients provided written informed consent.
Patients
Inclusion criteria were an age of 18 years of older, histo-
logically confirmed colorectal carcinoma, wild-type
KRAS tumours, first occurrence of metastatic disease, atleast one radiologically measurable lesion, a life expect-
ancy of ≥12 weeks, an Eastern Cooperative Oncology
Group (ECOG) Performance Status ≤1, and adequate
hematologic, hepatic and renal function. Patients with
prior exposure to anti-EGFR therapy or chemotherapy
for metastatic disease (with the exception of oxaliplatin
if completed ≥6 months prior to inclusion) were not eli-
gible for inclusion.Study treatment
Patients received a biweekly intravenous (IV) infusion of
cetuximab (500 mg/m2 on day 1) followed by FOLFOX-
4 (2-hour oxaliplatin 85 mg/m2 infusion on day 1 in tan-
dem with a 2-hour leucovorin 200 mg/m2 infusion on
day 1 and 2, and 5-FU as a 400 mg/m2 bolus followed
by a 22-hour 600 mg/m2 infusion on day 1 and 2).
Cetuximab was administered over 2 hours in the first
cycle, over 1.5 hours in the second cycle and over 1 hour
thereafter. Appropriate prophylactic medication was ad-
ministered to prevent the occurrence of acute hypersen-
sitivity reactions before each cetuximab administration.
Protocol dose modifications were permitted in the event
of predefined toxic effects related to chemotherapy or
cetuximab [17]. In the event of unacceptable toxicity due to
5-FU/leucovorin, oxaliplatin, or cetuximab, the agent
responsible could be discontinued and the patient
could continue with the other study medications.
However, protocol modifications did not allow the
maintenance of oxaliplatin as a monotherapy or in
combination with cetuximab. Treatment was continued
until disease progression, onset of unacceptable toxic
effects, a patient/physician request to discontinue, or
surgery for metastases.Study assessments
Pre-treatment evaluations included the determination of
KRAS mutation status. Mutation analysis was performed
centrally at the Hospital Universitario Mútua Terrassa.
Tumour DNA was extracted from formaldehyde-fixed
paraffin-embedded tissues. Mutant KRAS in exon 2 was
detected using a validated KRAS mutation kit (DxS
LTD., Manchester UK) that identifies seven somatic mu-
tations located in codons 12 and 13 using allele-specific
real-time PCR. The analysis was performed in an ABI
Prism 7300 instrument (Applied Biosystems).
Computed tomography (CT) or magnetic resonance
imaging (MRI) was performed at baseline, every 8 weeks
during the first 6 months of the study, and every
12 weeks thereafter until disease progression. Adverse
events were collected throughout the study period. All
adverse events recorded were graded according to the
Common Toxicity Criteria of the National Cancer
Institute (CTC-NCI) version 3.0.
Table 1 Demographic and clinical data at baseline in the
intention-to-treat population
Characteristic N = 99
Male, n (%) 66 (66.7)
White/Caucasian ethnicity, n (%) 98 (99.0)
Median age, years (range) 64.1 (34-82))
ECOG status, n (%)
0 51 (51.5)
1 48 (48.5)















Primary tumor site, n (%)
Colon 59 (59.6)
Rectum 40 (40.4)
Metastases sites*, n (%)
Liver 87 (87.9)
Lung 39 (39.4)
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The primary endpoint of the study was the objective re-
sponse rate (ORR) defined according to the Modified
Response Criteria in Solid Tumours (RECIST 1.1) [18].
Secondary endpoints included progression-free survival
(PFS), duration of response, overall survival (OS) and tox-
icity profile of biweekly cetuximab in combination with
FOLFOX-4. Patients who underwent surgery for metasta-
ses were censored at the date of surgery in the PFS ana-
lysis. Median PFS and OS following metastasectomy were
also assessed for this group of patients. The cut-off date
for collection of survival data was November 19th, 2012.
A sample size of 98 patients was calculated to detect a
95% confidence interval (CI) for the ORR of 50-70%,
assuming an estimated rate of 60% according to previ-
ous studies and an anticipated 10% of patient loss to
follow-up [9].
The intention to treat population (ITT) included all
patients that received at least one dose of the combin-
ation chemotherapy (four drugs) and had at least one
radiological assessment at 8 weeks. Safety analysis was
conducted in the group of patients that received at least
one dose of any of the four drugs (oxaliplatin, leucov-
orin, 5-FU or cetuximab).
Numerical variables were summarized as mean and
standard deviation (SD). For categorical variables, abso-
lute and relatives frequencies were calculated. Time-to-
event variables were analysed using the Kaplan-Meier
method. Relative dose intensity (RDI) was calculated by
dividing the dose intensity of the administered regimen
by the dose intensity of the drug in the standard planned
regimen. Data analysis was performed using the Statis-
tical Analysis System version 9.2 (SAS 9.2).Lymph nodes 27 (27.3)
Other 17 (17.1)
Prior therapy, n (%)
Adjuvant chemotherapy (FOLFOX) 9 (9.1%)
Neoadjuvant chemo-radiotherapy for rectal cancer 7 (7.1%)
Surgery 48 (48.5%)
Abbreviations: ECOG Eastern Cooperative Oncology Group, ITT Intention to
treat, Q1-Q3 Interquarile range.
*A patient may had metastases in more than one organ.Results
Patient disposition and baseline characteristics
From July 2009 until December 2011, 101 patients were
included in the study. Two patients immediately with-
drew their consent. The ITT population consisted of 99
patients. Safety analysis was carried out on the 99 patients
who received at least one dose of any component of the
study treatment. Demographic and clinical characteristics
at baseline are shown in Table 1. Median age of the pa-
tients was 64.1 years (range: 34-82 years). Thirty-five pa-
tients presented with metastases limited to the liver. The
median duration of follow-up was 17.8 months.Efficacy
The best confirmed ORR was 60.6% (95% CI, 50.3% to
70.3%) (4 complete and 56 partial responses) (Table 2).
Thirty patients (30.3%) had stable disease. Therefore, the
disease control rate (DCR) was 90.9% (95% CI, 83.4% to
95.8%). In the 60 patients with a partial or completeresponse, median time to onset of response was 1.9 months
and median duration of response was 8.6 months.
Objective disease progression was observed in 68 pa-
tients. Median PFS was 10.1 months (Q1-Q3, 6.5-14.8)
(Table 2; Figure 1). Time to progression, defined as time
from the first treatment administration to the first ob-
jective disease progression in the 60 patients who had a
complete/partial response, was 10.4 months (Q1-Q3,
6.8-17.9). At the time of data collection cut-off there
were 57 deaths (57.6%). The median OS was 20.8 months
(Q1-Q3, 11.6-32.8) (Table 2; Figure 2).




Complete response 4 (4.0)
Partial response 56 (56.6)
Stable disease 30 (30.3)
Progressive disease 5 (5.1)
Not available 4 (4.0)
ORR, % (95% CI) 60.6 (50.3 to 70.3)
DCR, % (95% CI) 90.9 (83.4 to 95.8)
Progression-free survival





Death, n (%) 57 (57.6)
Months of overall survival, median (Q1-Q3) 20.8 (11.6-32.8)
Abbreviations: CI confidence interval, DCR disease control rate, ITT intention-to-
treat, ORR objective response rate, Q1-Q3 Interquarile range.
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liver metastases, with complete surgical resection (R0)
observed in 18 (18.2%) patients. The median PFS and
OS after surgical resection of metastases were 12.6 months
and 29.5 months, respectively. Twenty-one patients
(80.8%) who underwent surgery for metastases received
adjuvant chemotherapy. Thirteen of the 21 patients
continued with cetuximab-containing regimens after
surgery.
Treatment exposure
The median duration of cetuximab treatment was
20.9 weeks (range: 1-148). The median cumulative
dose of cetuximab was 4659.4 mg/m2 and the median
intensity of dose per cycle was 447.1 mg/m2; there-
fore the median cetuximab dose used in this study
was similar to the recommended 500 mg/m2 dose.
Consequently, the median relative dose intensity was
89%, with a total of eighty-two patients (82.8%) re-
ceiving ≥80% relative dose intensity (RDI) of cetuxi-
mab. Thirty-nine patients (39.4%) had at least one
cetuximab dose reduction. Delays in cetuximab dosing
were mostly due to skin reactions. As for chemotherapy,
the median duration of oxaliplatin and 5-FU treatment
was 18.3 weeks (range: 1-46) and 22.9 weeks (range: 1-83),
respectively. A RDI ≥80% was achieved in 58 patients
(58.6%) for oxaliplatin and in 55 patients (55.6%) for 5-FU.
Two or more lines of treatment were received by 62.6%
of patients, whereas 5.1% of patients underwent surgery
and did not receive additional lines of treatment post-
surgery.Safety
Adverse events (AEs) of any grade occurring in at least
10% of patients and grade 3 or 4 AEs occurring in at
least 2% of patients are summarized in Table 3. Seventy-
seven patients (77.8%) presented at least one grade 3 or
4 AE. The most common grade 3 or 4 AEs were neutro-
penia (32.3%) and diarrhoea (13.1%).
For grade 3 or 4 special adverse events, 15.2% pa-
tients presented with acne-like rash, 6.1% presented
with nail toxicity (this special event category included
the preferred terms nail toxicity and paronychia) and
no patient presented with infusion-related reactions
(this special event category included the preferred
terms “infusion related reaction” and “pyrexia”). Hypo-
magnesemia was reported in only one patient (grade 4).
Cetuximab was discontinued in 33 patients (33.3%),
oxaliplatin was discontinued in 41 patients (41.4%) and
5-FU was discontinued in 25 patients (25.3%) due to
adverse events.
Disease progression was the primary cause of death
(91.2% of deaths). Two patients died due to an unrelated
AE and one patient died due to a related AE. This pa-
tient presented with pulmonary fibrosis that was consid-
ered related to oxaliplatin and/or cetuximab.
Discussion
This study showed that the efficacy of biweekly-
administered cetuximab in combination with FOLFOX-4
is similar to what has been reported for the standard
weekly cetuximab dosing regimen as first-line treatment
of wild-type KRAS mCRC. The ORR obtained in the
present study (61%) was similar to the figure reported in a
previous phase II study with a weekly administration of
cetuximab in combination with FOLFOX-4 [10]. A
similar ORR was also obtained (62%) in the biweekly
cetuximab arm of the recently published randomised
study performed by the Central European Co-operative
Oncology Group (CECOG) [19]. In the weekly cetuxi-
mab arm of that phase II study, a lower ORR was ob-
tained (53%). The CECOG trial was not powered to
establish non-inferiority of biweekly administration ver-
sus weekly administration of cetuximab, so further stud-
ies would be needed to confirm their findings.
The median PFS (10.1 months) observed is also in line
with the 8.3 months and 9.5 months reported in previ-
ous studies with weekly cetuximab combined with
FOLFOX-4, and very similar to the figure obtained in
the biweekly arm of the CECOG trial (9.2 months)
[10,19]. It was also slightly longer than the range of
8.4-9.1 months reported for standard weekly cetu-
ximab in combination with other oxaliplatin-based
chemotherapy regimens in patients with wild-type
KRAS mCRC [7,20]. Although the short median
follow-up of our study does not permit us to draw
Figure 1 Kaplan-Meier plot for progression-free survival in the intention to treat (ITT) population.
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obtained (20.8 months) was slightly shorter but con-
sistent with the median OS reported for standard
weekly cetuximab in combination with FOLFOX-4 and
in the biweekly arm of the CECOG trial [10,19].Figure 2 Kaplan-Meier plot for overall survival in the intention to treaComplete surgical resection of colorectal liver metas-
tases is potentially curative and provides clear survival
benefits in patients with disease confined to the liver.
Within this context, 35 out of 99 patients in our study
presented with only liver metastases. 26.3% of patientst (ITT) population.
Table 3 Adverse events
Adverse event Any grade Grade 3 or 4
Any adverse event* 97 (98.0%) 77 (77.8%)
Blood and lymphatic system disorders
Anaemia 11 (11.1%) 2 (2.0%)
Febrile neutropenia 6 (6.1%) 5 (5.1%)
Leukopenia 15 (15.2%) 1 (1.0%)
Neutropenia 49 (49.5%) 32 (32.3%)
Thrombocytopenia 23 (23.2%) 2 (2.0%)
Gastrointestinal disorders
Abdominal pain 30 (30.3%) 2 (2.0%)
Diarrhoea 58 (58.6%) 13 (13.1%)
Intestinal obstruction 8 (8.1%) 8 (8.1%)
Nausea 28 (28.3%) 2 (2.0%)
Stomatitis 52 (52.5%) 5 (5.1%)
Vomiting 21 (21.2%) 1 (1.0%)
General disorders and administration site disorders
Asthenia 65 (65.7%) 8 (8.1%)
Immune system disorders
Drug hypersensitivity 9 (9.1%) 3 (3.0%)
Metabolism and nutrition disorders 37 (37.4%) 4 (4.0%)
Anorexia 25 (25.3%) 2 (2.0%)
Musculoskeletal and connective tissue disorders
Back pain 8 (8.1%) 2 (2.0%)
Nervous system disorders
Dysaesthesia 11 (11.1%) 2 (2.0%)
Dysgeusia 12 (12.1%) 1 (1.0%)
Peripheral neuropathy 11 (11.1%) 2 (2.0%)
Neurotoxicity 22 (22.2%) 2 (2.0%)
Paraesthesia 40 (40.4%) 6 (6.1%)
Psychiatric disorders
Anxiety 3 (3.0%) 2 (2.0%)
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism 3 (3.0%) 2 (2.0%)
Skin and subcutaneous tissue disorders
Dry skin 23 (23.2%) 4 (4.0%)
Vascular disorders
Deep vein thrombosis 3 (3.0%) 2 (2.0%)
Special adverse event categories
Acne-like Rash 91 (91.9%) 15 (15.2%)
Infusion related reactiona 14 (14.1%) 0 (0.0%)
Nail toxicityb 28 (28.3%) 6 (6.1%)
*Listed are adverse events of any grade occurring in at least 10% of patients and adverse events of grade 3 or 4 occurring in at least 2% of patient.
aThis special event category included the preferred terms infusion related reaction and pyrexia.
bThis special event category included the preferred terms nail toxicity and paronychia.
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R0 resection rate was achieved in 18% of patients. This
R0 resection rate is higher than that reported in the
cetuximab weekly arm (5%) and in the cetuximab every
second week arm (10%) of the CECOG trial [10,19].However, in contrast to the CECOG trial metastases re-
sectability was not a selection criterion in the present
study. Therefore, while some patients were initially can-
didates for surgery, other patients presented with unre-
sectable metastases. In our study, surgical resected
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unresected patients. These results confirm the improved
prognosis of patients undergoing surgery for colorectal
liver metastases.
The toxicity profile of the biweekly administration of
cetuximab is also consistent with the known safety pro-
file of the standard weekly cetuximab dosing regimen.
The incidence rate of grade 3 or 4 AEs was in line with
that reported previously for cetuximab in combination
with FOLFOX-4 [10,18,19]. Therefore, a higher dose of
cetuximab administered on an every-2-weeks basis is
not associated with a greater incidence of grade 3 or 4
adverse events. As expected, the most common grade 3
or 4 adverse events were neutropenia and acne-like rash.
The high proportion of patients that required at least
one cetuximab dose reduction are attributable to dose
adjustments planned in case of dose delay of chemother-
apy due to haematological toxicity.
Conclusions
In conclusion, despite the known limitations of a non-
randomised single arm study, our results support the ad-
ministration of cetuximab in a dosing regimen more
convenient for both patients and healthcare providers.
The option to synchronise the administration of cetuxi-
mab and chemotherapy would reduce the number of
administration visits. Such reductions would improve
patient’s quality of life and simplify treatment adminis-
tration for healthcare workers. Additionally, the reduc-
tion in the number of visits would reduce the costs of
treatment of patients with mCRC without reducing the
efficacy previously observed for cetuximab combined
with FOLFOX-4.
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